Mega LifeSciences
Mega LifeSciences, a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Thailand (TH) and operates extensively across Southeast Asia. Founded in 1985, the company has established itself as a leader in the development and distribution of high-quality healthcare products, including dietary supplements, herbal medicines, and prescription pharmaceuticals.
With a commitment to innovation and quality, Mega LifeSciences offers a diverse range of products that cater to various health needs, setting itself apart through rigorous research and development. The company has achieved significant milestones, including expanding its market presence and enhancing its product portfolio, which has solidified its position as a trusted name in the industry. Recognised for its dedication to health and wellness, Mega LifeSciences continues to make strides in improving the quality of life for consumers across the region.
-7 vs industry average
Mega LifeSciences’s score of 31 is lower than 45% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Mega LifeSciences?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Mega LifeSciences's reported carbon emissions
Mega Lifesciences, a pharmaceutical preparation manufacturer headquartered in Thailand, reported a total of approximately 8.96 million kg CO2e in emissions for 2024. This figure encompasses Scope 1, 2, and 3 emissions. For 2023, the company's total emissions were approximately 9 million kg CO2e. In 2024, Mega Lifesciences's emissions breakdown included approximately 2.07 million kg CO2e for Scope 1 and about 6.47 million kg CO2e for Scope 2. Scope 3 emissions for the same year amounted to approximately 421,090 kg CO2e, with fuel and energy-related activities contributing about 421,000 kg CO2e within Scope 3. For 2023, Scope 1 emissions were approximately 1.81 million kg CO2e, while Scope 2 emissions totalled about 6.75 million kg CO2e. Scope 3 emissions for 2023 were approximately 439,530 kg CO2e. Earlier reporting periods show Scope 1 and 2 emissions for 2021 at approximately 6.84 million kg CO2e, and for 2020 at approximately 7.32 million kg CO2e. In 2019, Scope 1 and 2 emissions were reported as approximately 6.67 million kg CO2e, and in 2018, they were approximately 6.83 million kg CO2e. Mega Lifesciences's emissions data is cascaded from its parent company, Mega Lifesciences Public Company Limited, indicating a corporate family relationship where the subsidiary's performance data is reported. The company has not publicly disclosed specific reduction targets or commitments to initiatives like the Science Based Targets initiative (SBTi) or the Climate Pledge.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Mega LifeSciences’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Mega LifeSciences yet.
Scope 3 top emissions categories
1 of 15 categories disclosedSee all scope 3 categories
Already have an account? Sign in now
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project